Merit Financial Group’s Charles River Laboratories CRL Stock Holding History

Merit Financial Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342K	Buy	+1,507	New	+$268K	﹤0.01%	1735

Other funds holding CRL

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

CPCPP

Canada Post Corporation Pension Plan Toronto, Canada $2.87B AUM 37.96% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

CCMINC

Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $826M AUM 32.06% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Merit Financial Group's CRL Position: Q2 2026 in Review

Merit Financial Group opened a new position in Charles River Laboratories (CRL) in Q2 2026: 1,507 shares worth $342K. The stake represents ﹤0.01% of the portfolio and ranks #1735 among its holdings.

82 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Merit Financial Group held 1,507 shares of Charles River Laboratories worth $342K as of Q2 2026.
Charles River Laboratories was a new Merit Financial Group position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1735 holding.
82 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.